Association of sociodemographic and clinical factors with the quality of life of Brazilian individuals with Neurofibromatosis type 1: a cross-sectional study.

Autor: Bicudo NP; Department of Medicine, Universidade Federal de São Carlos, São Carlos, SP, Brazil., Germano CMR; Department of Medicine, Universidade Federal de São Carlos, São Carlos, SP, Brazil., de Moraes RT; Department of Medicine, Universidade Federal de São Carlos, São Carlos, SP, Brazil., de Avó LRDS; Department of Medicine, Universidade Federal de São Carlos, São Carlos, SP, Brazil., Ferner RE; National Neurofibromatosis Service, Department of Neurology, Guy's and St Thomas' NHS Foundation Trust, London, UK., Melo DG; Department of Medicine, Universidade Federal de São Carlos, São Carlos, SP, Brazil. Electronic address: dgmelo@ufscar.br.

Publikováno v: Anais brasileiros de dermatologia [An Bras Dermatol] 2024 Jul-Aug; Vol. 99 (4), pp. 520-526. Date of Electronic Publication: 2024 Mar 16.

Treatment of insulin poisoning: A 100-year review.

Autor: Moyns EJ; National Poisons Information Service (Birmingham Unit), City Hospital, Birmingham, UK., Ferner RE; National Poisons Information Service (Birmingham Unit), City Hospital, Birmingham, UK.; Institute of Clinical Sciences, University of Birmingham, Birmingham, UK.

Publikováno v: Diabetic medicine : a journal of the British Diabetic Association [Diabet Med] 2023 Jun; Vol. 40 (6), pp. e15076. Date of Electronic Publication: 2023 Mar 23.

Drug shortages. Part 2: Trends, causes and solutions.

Autor: Aronson JK; Centre for Evidence Based Medicine, Nuffield Department of Primary Care Health Sciences, Oxford, UK., Heneghan C; Centre for Evidence Based Medicine, Nuffield Department of Primary Care Health Sciences, Oxford, UK., Ferner RE; West Midlands Centre for Adverse Drug Reactions, City Hospital, Birmingham, UK.; School of Clinical and Experimental Medicine, University of Birmingham, Birmingham, UK.

Publikováno v: British journal of clinical pharmacology [Br J Clin Pharmacol] 2023 Oct; Vol. 89 (10), pp. 2957-2963. Date of Electronic Publication: 2023 Aug 06.

Platform trial design for neurofibromatosis type 1, NF2-related schwannomatosis and non-NF2-related schwannomatosis: A potential model for rare diseases.

Autor: Dhaenens BAE; Department of General Paediatrics, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands.; ENCORE Expertise Centre for Neurodevelopmental Disorders, Erasmus MC, Rotterdam, The Netherlands., Heimann G; Biostatistics & Pharmacometrics, Novartis Pharma AG, Basel, Switzerland., Bakker A; Children's Tumor Foundation, New York, New York, USA., Nievo M; Children's Tumor Foundation, New York, New York, USA., Ferner RE; Neurofibromatosis Service, Department of Neurology, Guy's and St. Thomas' NHS Foundation Trust London, Great Maze Pond, London, UK., Evans DG; Centre for Genomic Medicine, Division of Evolution, Infection and Genomic Sciences, University of Manchester, St Mary's Hospital, Manchester, UK., Wolkenstein P; Department of Dermatology, Henri-Mondor Hospital, Créteil, France., Leubner J; Department of Pediatric Neurology, Charité Universitätsmedizin Berlin-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany., Potratz C; Department of Pediatric Neurology, Charité Universitätsmedizin Berlin-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany., Carton C; Department of Human Genetics, KU Leuven, Leuven, Belgium., Iloeje U; Medical Affairs, SpringWorks Therapeutics, Stamford, Connecticut, USA., Kirk G; AstraZeneca Oncology R&D, Cambridge, UK., Blakeley JO; Department of Neurology, Neuro-Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Plotkin S; Cancer Center and Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA., Fisher MJ; Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA., Kim A; Division of Oncology, Children's National Hospital, Washington DC, District of Columbia, USA., Driever PH; Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany., Azizi AA; Division of Neonatology, Pediatric Intensive Care and Neuropediatrics, Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Wien, Austria., Widemann BC; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA., Gross A; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA., Parke T; Berry Consultants, Abingdon, UK., Legius E; Department of Human Genetics, KU Leuven, Leuven, Belgium.; Department of Clinical Genetics, UZ Leuven, Leuven, Belgium.; Full Member of the European Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS), Nijmegen, The Netherlands (E.L., R.O.)., Oostenbrink R; Department of General Paediatrics, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands.; ENCORE Expertise Centre for Neurodevelopmental Disorders, Erasmus MC, Rotterdam, The Netherlands.; Full Member of the European Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS), Nijmegen, The Netherlands.

Publikováno v: Neuro-oncology practice [Neurooncol Pract] 2024 Jan 04; Vol. 11 (4), pp. 395-403. Date of Electronic Publication: 2024 Jan 04 (Print Publication: 2024).

Free-of-charge medicine schemes in the NHS: A local and regional drug and therapeutic committee's experience.

Autor: O'Callaghan S; Formulary and Medicines Management Department, University College London Hospital NHS Foundation Trust, London, UK., Ferner RE; Institute of Clinical Sciences, University of Birmingham, Birmingham, UK., Barron A; Formulary and Medicines Management Department, University College London Hospital NHS Foundation Trust, London, UK., Saxby K; Formulary and Medicines Management Department, University College London Hospital NHS Foundation Trust, London, UK., Sofat R; Centre of Clinical Pharmacology and Therapeutics, Institute of Health Informatics, University College London, London, UK.

Publikováno v: British journal of clinical pharmacology [Br J Clin Pharmacol] 2022 Jun; Vol. 88 (6), pp. 2571-2580. Date of Electronic Publication: 2021 Oct 30.